- All US Corrona RA Registry patients who initiated tofacitinib 5 mg twice a day (BID)
or tofacitinib 11 mg once daily (QD) after it became available in February 2016
- Patients must have a follow-up visit at 6 months (+/- 3 months) after tofacitinib
initiation. These 6 month visits are part of routine practice and is not associated
with this protocol.
- Patients must have a valid clinical disease activity index (CDAI) at initiation and at
6-month follow-up visit
- There are no exclusion criteria for this study.